Elicio Therapeutics (ELTX) Cost of Revenue (2020 - 2021)
Elicio Therapeutics' (ELTX) quarterly Cost of Revenue came in at $433000.0 in Q4 2021, up 243.65% YoY from $126000.0 in Q4 2020, and up 243.65% on a QoQ basis from $126000.0 in Q4 2020.
Elicio Therapeutics (ELTX) Cost of Revenue (2020 - 2021) Analysis & Trends
Elicio Therapeutics (ELTX) has 2 years of Cost of Revenue data on file, last reported at $433000.0 in Q4 2021.
- Quarterly Cost of Revenue rose 243.65% year-over-year to $433000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $433000.0 (down 63.61% YoY) and the FY2021 annual result came in at $433000.0, down 63.61% from the prior year.
- Cost of Revenue rose to $433000.0 in Q4 2021, from $126000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $433000.0 in Q4 2021 to a low of $126000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 433,000.00 |
| Dec 31, 2021 | 433,000.00 |
| Dec 31, 2020 | 126,000.00 |
| Dec 31, 2020 | 126,000.00 |
| Sep 30, 2020 | 348,000.00 |
| Sep 30, 2020 | 348,000.00 |
| Jun 30, 2020 | 333,000.00 |
| Jun 30, 2020 | 333,000.00 |
| Mar 31, 2020 | 383,000.00 |
| Mar 31, 2020 | 383,000.00 |